Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5025 - Natural history of Alveolar Soft Part Sarcoma (ASPS): impact of Brain Metastases and Role of Anti-Angiogenic Therapies (AAT)


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Soft Tissue Sarcomas


Gabriel Malouf


Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387


G. Malouf1, G. Beinse1, O. Mir2, J. Adam3, P. Terrier3, J. Spano1, C. Honore4, A. Italiano5, J. Coindre6, J. Blay7, A. Lecesne8

Author affiliations

  • 1 Medical Oncology, Groupe Hospitalier Pitié Salpetriere, 75651 - Paris/FR
  • 2 Department Of Cancer Medicine, Gustave Roussy Cancer Campus, 94800 - Villejuif/FR
  • 3 Department Of Pathology, Gustave Roussy Cancer Campus, 94800 - Villejuif/FR
  • 4 Department Of Surgical Oncology, Gustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 5 Early Phase Trials And Sarcoma Units, Institute Bergonié, 33076 - Bordeaux/FR
  • 6 Department Of Biopathology, Institute Bergonié, 33076 - Bordeaux/FR
  • 7 Department Of Adult Medical Oncology, Centre Leon Berard, 69008 - Lyon/FR
  • 8 Department Of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif/FR


Abstract 5025


ASPS is a rare sarcoma subtype with clinical specificities, such as an indolent behavior, brain metastasis and resistance to doxorubicin. AAT have shown clinical activity in this setting, but little is known on the optimal therapeutic strategy, and the management of brain metastasis (BM).


We retrospectively analyzed patients (pts) treated in 3 referral centers of the French Sarcoma Group. Factors associated with BM development and overall survival (OS) were analyzed. In addition, progression-free survivals (PFS) under AAT in patients with and without BM were reported.


We identified 75 pts [median age at diagnosis: 23 (5-96 years), 61% females]. Among those, 31 (41%) pts had documented synchronous lung metastasis (LM), and none had BM. Median OS in pts with localized and metastatic disease were 279 months, (95% CI, 279-NR) and 74 months (95% CI, 62-144) (Log-rank, p = 0.002), respectively. Only surgical complete resection (R0) was associated with better OS in localized disease (HR = 4.3; (95% CI, 1-19.3), p = 0.056). Fifty-two (69%) pts had documented LM in the course of the disease; among those, 13 (17%) pts developed BM within a median interval of 35 months (95% CI, 17-48) from LM. Initial tumor size was associated with BM-free-survival (≥5cm vs


These data highlight the indolent course of the disease leading to BM, which turned a shift in the course of the disease, along with limited efficacy of AAT in this setting. Furthermore, they suggest that the appropriate timing for AAT introduction has to be discussed in an individual basis considering the PFS/OS ratio in pts with metastatic disease.

Clinical trial identification

Legal entity responsible for the study

Institut Gustave Roussy




G. Malouf: Consulting: Pfizer, BMS, Novartis Research grant: Pfizer, Novartis. O. Mir: Speaker: Lilly, Roche Consulting: Amgen, Astra-Zeneca, Bayer, Blueprint, BMS, Lilly, Novartis, Pfizer, Roche, Servier. J-P. Spano: conflict of interest with the following companies: Pfizer, BMS, MSD, Roche. J-Y. Blay: Research support: Novartis, Roche, GSK, Bayer, Pfizer. A. Lecesne: Honoraria: Amgen, Novartis, Pharmamar, Pfizer, Lilly. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.